SCHEMBL19002484

SCHEMBL19002484

CCCC(=O)NCc1ccc(C#N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
EPHX2 P34913 2/20 0.54
LOXL2 Q9Y4K0 1/20 0.53
HPGD P15428 3/20 0.53
ALDH1A1 P00352 1/20 0.53
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13968726 0.95 CYP3A4 (0.52) CYP3A4CYP2C19L3MBTL1EPHX2LOXL2
SCHEMBL9787424 0.88 EPHX2 (0.67) EPHX2HPGDALDH1A1HDAC3HDAC4
SCHEMBL17372408 0.87 CA12 (0.50) EPHX2LOXL2HPGDALDH1A1CA12
SCHEMBL19049390 0.87 LOXL2 (0.56) EPHX2LOXL2CA12CA1CA2
SCHEMBL19002485 0.82 ERCC1 (0.61) CYP3A4CYP2C19L3MBTL1EPHX2
SCHEMBL18134836 0.81 CYP3A4 (0.65) CYP3A4CYP2C19L3MBTL1EPHX2HPGD
SCHEMBL22609193 0.81 RAB9A (0.46) CYP3A4CYP2C19L3MBTL1EPHX2LOXL2
SCHEMBL21276486 0.80 HPGD (0.53) EPHX2LOXL2HPGDALDH1A1CA12
SCHEMBL5315364 0.80 EPHX2 (0.52) EPHX2LOXL2HPGDALDH1A1CA12
SCHEMBL7934897 0.80 EPHX2 (0.52) EPHX2LOXL2HPGDALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 CYP3A4 4589/4885CYP2C19 4701/4885L3MBTL1 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.